Announcement • Aug 13
Aclarion Receives Notice Of Allowance For Patent Advancing Accuracy And Adoption Of Nociscan's MR Spectroscopy Scan Process Aclarion received a Notice of Allowance for U.S. Patent Application titled “Multi-Voxel Prescription for Lumbar Disc Evaluation.” Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow. Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers. Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics. The allowed claims address a significant efficiency and quality challenge in MRS-based disc evaluation. By displaying both plan and shifted voxel locations during scan prescription, the innovation is designed to reduce the trial-and-error associated with voxel positioning, minimize the need for multiple scan series when optimal placement is uncertain, and lower the chance of a repeat study due to suboptimal voxel placement. At a technical level, the patent covers Aclarion's method for precisely positioning the MRS sampling locations within the lumbar disc during scan setup. Nociscan analyzes chemical shifts in intervertebral discs, and scanning these small anatomical structures precisely presents a meaningful technical challenge. Different chemical shifts can correspond to different physical sampling locations, making it critical that the scan does not inadvertently extend beyond the disc boundary and sample adjacent tissue. This patent covers methods and systems that account for this effect during scan prescription and ensure that the data Nociscan analyzes reflects the disc itself, not surrounding structures or unwanted endplate lipid signals. These capabilities are designed to improve MRS data reliability, simplify the acquisition workflow, and reduce scan variability across sites and MRI technologists. Once issued, the patent would extend Aclarion's intellectual property protection into the MRS scan-prescription stage, complementing the Company's broader portfolio of over 65 issued and pending patents worldwide, covering spectroscopy acquisition, data processing, biomarkers, and analytics. Chronic low back pain is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. When used with other diagnostic tools, Nociscan demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. Announcement • Jul 07
Aclarion Announces Texas Spine Care Center as New CLARITY Site Aclarion, Inc. announced Texas Spine Care Center as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial. The CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery. CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain. Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI). Texas Spine Care Center is a San Antonio-based orthopedic spine practice with two locations dedicated exclusively to spine care. The practice offers a comprehensive range of surgical and non-surgical treatment options, with a patient care philosophy centered on understanding the precise source of a patient's pain before determining the best course of treatment. Texas Spine Care Center joins a growing network of high-volume CLARITY trial sites including Johns Hopkins University, Northwestern Medicine, Advocate Aurora Research Institute, Texas Back Institute, Keck Medicine at USC, UHealth — University of Miami Health System, Scripps Health and Lanman Spinal Neurosurgery. The principal investigator for the trial is Dr. Nicholas Theodore, Chairman of Neurosurgery at the University of Arizona College of Medicine – Phoenix. The CLARITY trial is a 300-patient, prospective, randomized, multi-center study evaluating Nociscan in patients undergoing surgical treatment (Fusion /TDR) for discogenic low back pain. The primary endpoint is change in back pain as measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints collected. The company anticipates having an initial internal data readout and an expected public disclosure of early interim results in Fourth Quarter 2026. Chronic low back pain is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. Announcement • Jun 09
Echo Lake Capital cancelled the acquisition of Aclarion, Inc. (NasdaqCM:ACON). Echo Lake Capital proposed to acquire Aclarion, Inc. (NasdaqCM:ACON) on May 28, 2026. Echo Lake Capital offered to acquire Aclarion for $4 per share in cash and contingent value rights.
The transaction is subject to approval of merger agreement by target board.
Goodwin Procter LLP acted as legal advisor for Aclarion, Inc.
Echo Lake Capital cancelled the acquisition of Aclarion, Inc. (NasdaqCM:ACON) on June 8, 2026. 
